BCL2 and diffuse large B-cell lymphoma: In a preliminary experiment, using a combinatorial high-throughput drug screening (HTS) approach we first combined two DDR inhibitors (the CHK1/CHK2 inhibitor AZD-7762 and the selective CHK1 inhibitor MK-8776) with the BCL-2 inhibitor Venetoclax in 10 DLBCL cell lines.